SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2003-10-24

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BBRC.2003.09.114PMID 14550307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.

  2003cited by this paper
• Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors.

  2002cited by this paper
• Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development

  2002cited by this paper
• Paradigms of Growth Control: Relation to Cdk Activation

  2002cited by this paper
• Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development

  2002cited by this paper
• Pharmacological inhibitors of cyclin-dependent kinases.

  2002cited by this paper
• Structure-based design of cyclin-dependent kinase inhibitors.

  2002cited by this paper
• The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.

  2002cited by this paper
• Complexities in the development of cyclin-dependent kinase inhibitor drugs.

  2002cited by this paper
• Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.

  2001cited by this paper
• Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.

  2001cited by this paper
• A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.

  2001cited by this paper
• Crystallographic Approach to Identification of Cyclin-dependent Kinase 4 (CDK4)-specific Inhibitors by Using CDK4 Mimic CDK2 Protein*

  2001cited by this paper
• Cyclin‐dependent kinase inhibitors for treating cancer

  2001cited by this paper
• Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.

  2001cited by this paper
• VEGF receptor signaling in tumor angiogenesis.

  2000cited by this paper
• Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.

  2000cited by this paper
• Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

  2000cited by this paper
• Anticancer drug targets: cell cycle and checkpoint control.

  1999cited by this paper
• CDK inhibitors: positive and negative regulators of G1-phase progression.

  1999cited by this paper
• Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.

  1999cited by this paper
• Four-dimensional control of the cell cycle

  1999cited by this paper
• CDK inhibition and cancer therapy.

  1999cited by this paper
• Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

  1998cited by this paper
• Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.

  1998cited by this paper
• Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.

  1997cited by this paper
• Cyclin-dependent kinases: engines, clocks, and microprocessors.

  1997cited by this paper
• Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2

  1997cited by this paper
• Cyclin from sea urchins to HeLas: making the human cell cycle.

  1996cited by this paper
• Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

  1995cited by this paper
• Cyclin‐dependent protein kinases: Key regulators of the eukaryotic cell cycle

  1995cited by this paper
• Crystal structure of cyclin-dependent kinase 2

  1993cited by this paper
• Purification and crystallization of human cyclin-dependent kinase 2.

  1993cited by this paper

• Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics.

  2025cites this paper
• 2,4,6-Trimethoxy chalcone derivatives: an integrated study for redesigning novel chemical entities as anticancer agents through QSAR, molecular docking, ADMET prediction, and computational simulation

  2024influential citation
• High-throughput screening identifies cell cycle-associated signaling cascades that regulate a multienzyme glucosome assembly in human cells

  2023cites this paper
• Accelerating and Automating the Free Energy Perturbation Absolute Binding Free Energy Calculation with the RED-E Function

  2023cites this paper
• High-content quantitative high-throughput screening identifies a cell cycle-associated signaling cascade that regulates a multienzyme metabolic assembly for glucose metabolism

  2022cites this paper
• A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights

  2021cites this paper
• A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.

  2020cites this paper
• How Good is Jarzynski’s Equality for Computer-Aided Drug Design?

  2020cites this paper
• Advances in covalent kinase inhibitors.

  2020cites this paper
• Development of Small Molecule Therapies Targeting Regeneration for the Treatment of Duchenne Muscular Dystrophy

  2018cites this paper
• How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

  2018cites this paper
• Cyclin Dependent Kinase Inhibitors as Drug Targets for Cancer-A Review

  2017cites this paper
• SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.

  2017cites this paper
• Development of fluorescent biosensors and inhibitors to probe and target CDK5/p25 in glioblastoma

  2016influential citation
• Isatin inhibits the proliferation and invasion of SH-SY5Y neuroblastoma cells.

  2016cites this paper
• Inhibition of cyclin-dependent kinase CDK1 by oxindolimine ligands and corresponding copper and zinc complexes

  2015cites this paper
• Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors

  2015cites this paper
• ATP-noncompetitive CDK inhibitors for cancer therapy: an overview

  2013cites this paper
• Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.

  2013cites this paper
• Indolin-2-Ones in Clinical Trials as Potential Kinase Inhibitors: A Review

  2012cites this paper
• Irreversible Nek2 kinase inhibitors with cellular activity.

  2011cites this paper
• p57 is required for quiescence and maintenance of adult hematopoietic stem cells.

  2011cites this paper
• Novel Strategy for Three-Dimensional Fragment-Based Lead Discovery

  2011cites this paper
• Cell Stem Cell Role of p 57 in Adult Hematopoietic Stem Cells long-term repopulating capacity

  2011cites this paper
• Chemical modulation of memory formation in larval zebrafish

  2011cites this paper
• Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.

  2011cites this paper
• B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest

  2010cites this paper
• RSK2 Binding Models Delineate Key Features for Activity.

  2010cites this paper
• Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship.

  2010cites this paper
• Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

  2010cites this paper
• Rough set-based SAR analysis: An inductive method

  2010cites this paper
• Cyclin‐dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T‐cell leukemia Jurkat cells

  2010cites this paper
• Synthesis of 1-(2,6-dichlorophenyl)-3-methylene-1,3-dihydro-indol-2-one derivatives and in vitro anticancer evaluation against SW620 colon cancer cell line.

  2009cites this paper
• Molecular dynamics, density functional, ADMET predictions, virtual screening, and molecular interaction field studies for identification and evaluation of novel potential CDK2 inhibitors in cancer therapy.

  2008cites this paper
• Synthesis and biological evaluation of diversely substituted indolin-2-ones.

  2008cites this paper
• Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.

  2008cites this paper
• CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.

  2008cites this paper
• Identification of RIP1 kinase as a specific cellular target of necrostatins.

  2008cites this paper
• A Simple and Efficient Docking Method to the Cyclin-Dependent Kinase 2

  2007cites this paper
• In-vitro antiproliferative activities and kinase inhibitory potencies of glycosyl-isoindigo derivatives

  2007cites this paper
• Serine 64 Phosphorylation Enhances the Antiapoptotic Function of Mcl-1*

  2007cites this paper
• Synthesis and antiproliferative activities of diversely substituted glycosyl-isoindigo derivatives.

  2006cites this paper
• Oxindole Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents

  2006cites this paper
• Review of selected patents for cancer therapy targeting tumor angiogenesis.

  2006cites this paper
• Inhibition of RET tyrosine kinase by SU5416.

  2006cites this paper
• Protein structures in virtual screening: a case study with CDK2.

  2006cites this paper
• Synthesis and antiproliferative activities of indolin-2-one derivatives bearing amino acid moieties.

  2006cites this paper
• Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations.

  2006cites this paper
• Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

  2006cites this paper
• Biophysical characterization of an indolinone inhibitor in the ATP-binding site of DNA gyrase.

  2006cites this paper
• Selectivity and potency of cyclin-dependent kinase inhibitors

  2006cites this paper
• inhibitors: a survey of the recent patent literature

  2005cites this paper
• Mechanism of Aurora B activation by INCENP and inhibition by hesperadin.

  2005cites this paper
• Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.

  2005cites this paper
• Cyclin-dependent kinase inhibitors: a survey of the recent patent literature

  2005cites this paper
• Synthesis of glycosyl-isoindigo derivatives

  2004cites this paper